Gland Pharma Ltd. (GLAND) Share Price Hits Fresh 52-Week High

Gland Pharma Ltd. Share Price has reached a fresh 52-week high of Rs 2,599.85, reflecting a 0.42% increase from the previous close of Rs 2,577.3. The stock opened at Rs 2,599.85 and recorded a low of Rs 2,562.25 during the day. With a market capitalisation of Rs 41,314.25 crore, Gland Pharma Ltd. is attracting significant attention in the market. This milestone highlights the company's strong performance and investor interest, despite the absence of a specific catalyst in the supplied data.

Gland Pharma Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,588.2
Previous Close	Rs 2,577.3
Today's Change	+Rs 10.9 (+0.42%)
Day Open	Rs 2,599.85
Fresh 52-Week High	Rs 2,599.85
Day Low	Rs 2,562.25
Current Volume	4,432
Turnover	Rs 1.15 crore
Market Capitalisation	Rs 41,314.25 crore

Gland Pharma Ltd. (GLAND) traded at Rs 2,588.2. versus the previous close of Rs 2,577.3, a rise of 0.42%. The stock opened at Rs 2,599.85, reached Rs 2,599.85, touched Rs 2,562.25. Reported volume was 4,432.

Today, Gland Pharma Ltd. Share Price experienced a 0.42% increase, closing at Rs 2,588.2. The stock reached a fresh 52-week high of Rs 2,599.85, surpassing its previous close of Rs 2,577.3. The day's trading began at Rs 2,599.85, with a low of Rs 2,562.25. The turnover for the day was Rs 1.15 crore, with a volume of 4,432 shares, indicating moderate market participation. This price action suggests strong investor interest, setting the stage for further analysis of the company's fundamentals.

Gland Pharma Ltd. (GLAND) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 41,314.25 crore
P/E Ratio	39.39x
P/B Ratio	7.98x
ROE	28.21%
ROCE	26.35%

Gland Pharma Ltd. was valued at a P/E ratio of 39.39x, a P/B ratio of 7.98x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	39.39x
Benchmark Median P/E	20.89x
Benchmark Average P/E	73.74x
Benchmark P/E Range	0x to 3,364.06x
Company P/B Ratio	7.98x
Benchmark Median P/B	1.9x
Company ROE	28.21%
Benchmark Median ROE	10.92%
Company ROCE	26.35%
Benchmark Median ROCE	13.29%
Company Market Capitalisation	Rs 41,314.25 crore
Benchmark Median Market Cap	Rs 139.24 crore

Gland Pharma Ltd. (GLAND) is classified under sector: Healthcare.

Gland Pharma Ltd. (GLAND) has a P/E ratio of 39.39x, which is above the benchmark median of 20.89x, a difference of +88.56%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Gland Pharma Ltd. (GLAND) has a ROE of 28.21%, which is above the benchmark median of 10.92%, a difference of +158.33%. Gland Pharma Ltd. (GLAND) has a ROCE of 26.35%, which is above the benchmark median of 13.29%, a difference of +98.27%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Kwality Pharmaceuticals Ltd.	KPL	2,683.28	39.39	7.98	28.21	26.35
Beta Drugs Ltd.	BETA	2,474.26	62.88	9.95	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,421.1	34.54	6.99	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,416.82	171.93	3.18	13.9	12.97
Hester Biosciences Ltd.	HESTERBIO	2,111.45	15.25	4.57	16.17	14.12

Gland Pharma Ltd. (GLAND) has a P/E ratio of 39.39x compared with the displayed peer median of 39.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Gland Pharma Ltd. (GLAND) has a market capitalisation of Rs 41,314.25 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Gland Pharma Ltd.

• Gland Pharma Ltd. Share Price reached a fresh 52-week high at Rs 2,599.85.
• Strong fundamentals with high ROE and ROCE.
• Competitive valuation compared to sector benchmarks.
• Significant market capitalisation within the Healthcare sector.

About Gland Pharma Ltd.

Gland Pharma Ltd. is a prominent player in the Healthcare sector, specialising in the development, manufacturing, and marketing of complex injectables. The company operates across various therapeutic segments, including oncology, cardiology, and anti-infectives. With a strong focus on research and development, Gland Pharma Ltd. has established a robust pipeline of products, catering to both domestic and international markets. Its commitment to quality and innovation has positioned it as a leader in the pharmaceutical industry.

Track Gland Pharma Ltd. Share Price on Univest

Use Gland Pharma Ltd. (GLAND) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Gland Pharma Ltd. Share Price, along with technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed about the latest developments and make data-driven investment decisions.

Frequently Asked Questions

What is the current share price of Gland Pharma Ltd.?

Ans. The current share price of Gland Pharma Ltd. is Rs 2,588.2, reflecting a 0.42% increase from the previous close of Rs 2,577.3. The stock moved 0.42% during the session. The intraday range extended from Rs 2,562.25 to Rs 2,599.85.

What is the 52-week high of Gland Pharma Ltd.?

Ans. Gland Pharma Ltd. has reached a fresh 52-week high of Rs 2,599.85, indicating strong market performance and investor interest. The stock moved 0.42% during the session. The intraday range extended from Rs 2,562.25 to Rs 2,599.85.

How does Gland Pharma Ltd.'s P/E ratio compare to the sector?

Ans. Gland Pharma Ltd.'s P/E ratio of 39.39 is above the sector median of 20.89 but below the sector average of 73.74, indicating a balanced valuation. The company trades at a P/E ratio of 39.39x.

How does Gland Pharma Ltd. compare to its peers?

Ans. Gland Pharma Ltd. exhibits a competitive edge with a higher ROE and ROCE compared to most peers, and a significantly larger market capitalisation. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd.

What is the market capitalisation of Gland Pharma Ltd.?

Ans. Gland Pharma Ltd. has a market capitalisation of Rs 41,314.25 crore, making it a major player in the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.39x.

What is the ROE of Gland Pharma Ltd.?

Ans. Gland Pharma Ltd. has an impressive ROE of 28.21%, significantly higher than the sector median of 10.92%, indicating strong profitability. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.

What is the ROCE of Gland Pharma Ltd.?

Ans. Gland Pharma Ltd. has a ROCE of 26.35%, surpassing the sector median of 13.29%, reflecting efficient capital use. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.

How can I track Gland Pharma Ltd. Share Price?

Ans. Investors can track Gland Pharma Ltd. Share Price, technical indicators, and market insights on Univest for informed investment decisions. The stock moved 0.42% during the session. The intraday range extended from Rs 2,562.25 to Rs 2,599.85.